New York, New York--(Newsfile Corp. - May 19, 2021) - PCG Digital -- Continuing the barrage of good-news announcements that began with its first quarter results and strong balance sheet reports, Alkido Pharma Inc. (NASDAQ: AIKI) was recently highlighted in two key investor features. A biotechnology company based in New York, Alkido Pharma is working to develop a diverse portfolio of early and mid-stage small-molecule anti-cancer therapeutics. The newsworthy company also partners with leading universities, hospitals and medical schools for pipeline expansion and to treat various cancers and viral infections, including significant focus on the influenza virus, Ebola and Covid-19.
Notably, InvestorPlace observed that AIKI was a company that could potentially "extend, improve and possibly save the lives of millions" and was one to "keep an eye on," thanks to the biotech company's "interesting angle" of using psychedelics to treat diseases such as cancer. InvestorPlace was also impressed by AIKI's considerable pipeline, including its antiviral treatments for Covid-19 and influenza, and its robust research program.
StockMatusow’s blog on Seeking Alpha also put AIKI in the spotlight, noting the anticipated milestones with Covid-related news, the addition of a new board member with extensive virology experience and a CEO who is buying stock on the open market. It’s no surprise the world's largest investor community platform is paying attention to AIKI’s recent advancements. Carrying a strong pipeline, low burn rate, and a secure balance sheet, the Company announced First Quarter 2021 Results and Provided a Corporate Update, May 11, 2021, giving investors more reasons to add AIKI to their watchlist.
What are those factors?
More and more investors and investor conferences across the globe are paying closer attention to Alkido Pharma with the anticipated publication of potentially groundbreaking testing data and technology advancements in the next month. With the strongest cash balance in company history, as well as a stock trading below cash value and a low burn rate, AIKI will likely garner more headlines and feature stories in the near term.
The good news continues with word of the company's strong pipeline with multiple catalysts to include advanced human trials for prostate cancer, not to mention expanded partnerships with world-class universities, treatments to help veterans suffering from post-traumatic stress disorder (PTSD) and more progress in optimizing anti-virals.
As Alkido is on deck to present at three big investor conferences - the Benzinga Global Small Cap Conference, the Investor Summit Group's Conference and the LD Micro Invitational Conference - in the days to come, investors can likely expect more news and more excitement from this innovative biotech.
Disclaimer
This communication was produced by PCG Digital Holdings, LLC, an affiliate of PCG Advisory Inc., (together "PCG"). PCG is an integrated investor relations, communications and strategic advisory firm. The information contained on this may be 'Paid Advertising' for purposes of Section 17(b) of the Securities Act of 1933, as amended (together with the rules and regulations there under, the "Securities Act"). PCG may be compensated by respective clients for publicizing information relating to its client's securities. For more information in terms of compensation received for services provided by PCG, see the pertinent advertising materials relating to the respective client. By accessing this Site and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy.
PCG is not a registered or licensed broker, dealer, broker-dealer, investment adviser nor investment manager, nor does PCG engage in any activities that would require such registrations. PCG does not provide investment advice, endorsement, analysis or recommendations with respect to any securities, and its services to or statements about its clients should never be construed as any endorsement of or opinion about any security of any client. No information contained in this communication constitutes an offer to sell, a solicitation of an offer to buy, or a recommendation of any security or any other similar product or service regardless of whether such security, product, or service is referenced in this communication. Further, nothing in this communication is intended to provide tax, legal, or investment advice and nothing in this communication should be construed as a recommendation to buy, sell or hold any investment or security or to engage in any investment strategy or transaction. For full disclaimers, including compensation received for professional services, please visit www.pcgadvisory.com/disclosures.
Contact: info@pcgadvisory.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/84461
